Objective. Rheumatoid arthritis (RA) is considered to be a prototypical autoimmune disorder. Several mechanisms have been proposed for the known pathologic function of B cells in RA, including antigen presentation, cytokine secretion, and humoral immunity. The aim of this study was to address the function of B lymphocytes in experimental arthritis.
Methods. We mapped the adaptive immune response following collagen-induced arthritis (CIA). We subsequently monitored these responses and disease outcomes in genetically modified mouse strains that lack mature B cell or germinal center (GC) functionality in a B cell-intrinsic manner.
Results. Following primary immunization, the draining lymph nodes broadly reacted against type II collagen (CII) with the formation of GCs and T cell activation. Mice that lacked mature B cell function were fully protected against CIA and had a severely attenuated ability to mount isotype-switched humoral immune responses against CII. Almost identical results were observed in mice that were selectively deficient in GC responses. Importantly, GC-deficient mice were fully susceptible to collagen antibody-induced arthritis.
Conclusion. We identified GC formation and anticollagen antibody production as the key pathogenic functions of B cells in CIA. The role of B cells in RA is likely to be more complex. However, targeting the GC reaction could allow for therapeutic interventions that are more refined than general B cell depletion.
Rheumatoid arthritis (RA) is a common autoimmune disease that leads to chronic destruction of the joints. Similar to what is observed in other autoimmune disorders, self-reactivity begins years before the clinical onset of RA, with the presence of circulating autoantibodies. In otherwise healthy individuals destined to develop RA, the first antibodies to appear are rheumatoid factors (RFs) (1), followed by antibodies to citrullinated proteins (2) . Around the time of disease onset, a complex pattern of different antibodies is detectable, including antibodies to joint proteins such as type II collagen (CII) (3) . Because these increased autoantibody levels are genetically associated with major histocompatibility complex (MHC) class II genes, it is likely that activation of autoreactive B cells is T cell dependent. The mechanisms of activation and the function of different B cell subsets remain unknown.
The use of animal models has provided important insight into the pathogenesis of RA, in particular the use of the collagen-induced arthritis (CIA) model (4) . CIA invokes T cell-and B cell-mediated immune responses against CII. Antibodies recognizing CII are considered to be a central pathogenic factor in CIA, because they can bind and destabilize cartilage, forming local immune complexes that can trigger synovial cell activation and later neutrophil infiltration of the joints (5, 6) . Similar antibody specificities that occur in CIA can also be observed in clinical subsets of RA (7) . Notably, mice that are genetically deficient in B cells and hence lack antibodies are protected against CIA (8) , and B cell-depleting anti-CD20 therapy can also prevent CIA (9) . The efficacy of anti-CD20 therapy in RA patients has made identifying the B A long-recognized histologic feature of RA is the presence of germinal centers (GCs) in inflamed joint tissue (10, 11) . GCs also form in rodents following the induction of CIA, in both the limbs and secondary lymphoid tissue (12, 13) . GCs are a major source of somatically mutated and class-switched antibodies, and the GC reaction generates memory B cells and plasma cells, thereby increasing the overall titers of antibodies. It has therefore been proposed that the GC reaction is an important contributor to RA (14) .
Although B cells are clearly important for the development of experimental arthritis, it is currently unknown whether the formation of GCs and subsequent autoantibody production represent crucial pathogenic B cell functions. It is possible that other B cell functions in addition to humoral responses, such as antigen presentation or cytokine secretion, could be critical, as has been shown in other autoimmune diseases (15) . Additionally, spleens that develop in genetically B cell-deficient mouse strains display several defects in splenic dendritic cell populations (16) that can alter T helper cell responses. Interestingly, isolated pathogenic antibodies recognizing CII have a germline configuration (17) , and anti-CII antibodies with somatic mutations can be reverted to germline configuration without loss of antigen recognition (18) . Furthermore, Cd4 -/-mice, which have attenuated GC responses, are still susceptible to CIA (19, 20) or are only partially protected (21) , whereas Tcrb -/-(a/b T celldeficient) mice are completely protected (22) . Hence, although functional T cells are required for CIA, the requirement of B cells through GC-derived pathogenic antibody production is not known.
In this report, we present evidence that the GC reaction is absolutely required for CIA. We created novel mice that are genetically susceptible to CIA but are unable to form GCs or alternatively have largely lost mature B cell function. These mice were completely protected against CIA. Furthermore, resistance to arthritis could be bypassed through injection of pathogenic anti-CII antibodies. Thus, our findings support the proposal that B cells have a causal function in CIA via the formation of GCs, which subsequently leads to the production of pathogenic antibodies.
MATERIALS AND METHODS
Animals. All animals were housed, bred, and maintained under specific pathogen-free conditions at the animal housing facility at the Karolinska Institutet Medical Clinical evaluation of arthritis. After induction of arthritis, scoring of CIA was performed in a blinded manner every day or twice daily. CAIA was scored every day. Arthritis development was scored using a macroscopic scoring system. A score of 1 was given for each inflamed toe or knuckle, and a score of 5 was given for an inflamed wrist or ankle, resulting in a maximum possible score of 15 per limb and a total possible score of 60 per mouse.
Confocal microscopy preparation. Inguinal lymph node (LN) sections (10 mm thick) were fixed in ice-cold acetone and blocked with Fc Block (CD16/CD32) in phosphate buffered saline (PBS) and 0.1% bovine serum albumin prior to incubation with Alexa Fluor 488-conjugated antibody, GL7, and PerCP-conjugated IgD (11-26c.2a), and counterstaining with DAPI. Confocal images were obtained using a Leica TCS inverted microscope.
Flow cytometric analysis. Spleens and lymph nodes were fractionated to a single-cell suspension. Erythrocytes were lysed for 5 minutes at room temperature followed by an additional 5 minutes on ice with 1 ml of ACK Lysing Buffer. The following antibodies were used: CD3e (Pacific Blue-conjugated 500A2 or PerCP-conjugated 145-2C11), CD4 (allophycocyanin [APC]-H7-conjugated GK1.5), CD8 (fluorescein isothiocyanate [FITC]-conjugated 53-6.7), CD44 (phycoerythrin [PE]-conjugated IM7), CD62L (APC-conjugated MEL-14), B220 (APC-Cy7-conjugated RA3-6B2), CD19 (APCconjugated 1D3), GL7 (APC-conjugated GL7), CD95 (PE-Cy7-conjugated Jo2), IgD (PerCP-conjugated 11-26c.2a), CD21 (FITC-conjugated 7G6), and CD23 (PE-Cy7-conjugated B3B4).
For intracellular staining, following staining for the extracellular markers, splenocytes were treated using a FoxP3/ MHC class II-loaded CII peptide GalHyK264 tetramers were synthesized as previously described (27) . Samples were acquired with a Dako CyAn flow cytometer (Beckman Coulter) and analyzed using FlowJo software.
Serum and immunoglobulin measurements. Plates were coated overnight with IgG heavy and light chains (2.5 lg/ml) or CII (10 lg/ml) in PBS at 4°C. The plates were then blocked with 1% bovine serum albumin (Sigma) in PBS for 1 hour at room temperature. Total IgG, IgM, and CII-specific antibody responses were determined by adding sample sera (diluted 1:1,000 1:5,000, 1:25,000, 1:125,000, and 1:625,000) in PBS to the various coated plates for 2 hours at room temperature.
Antibody binding was detected with alkaline phosphatase-conjugated goat anti-mouse total IgG, IgG1, or IgM and phosphatase substrate dissolved in 1M diethanolamine. Absorbance at 405 nm was measured in duplicate samples. CII-positive mouse serum (2.0-0.062 lg/ml) was used as a standard for the CII-specific autoantibodies. SoftmaxPro software was used to determine sample concentrations, using a 4-parameter logistic regression curve.
Statistical analysis. GraphPad Prism was used for statistical analysis.
RESULTS
Kinetics of the adaptive immune response to CIA. To determine the contribution of the GC reaction to the development of CIA, we first monitored the kinetics of GC formation following immunization. We monitored the clinical scores and incidence of CIA in C57/B6N mice that express MHC class II H-2 q . The MHC class II allele A q is required for antigen presentation of the immunodominant CII 260-270 peptide (28). Mice received primary immunization with heterologous rat CII in complete Freund's adjuvant and secondary immunization with CII in incomplete Freund's adjuvant 35 days later (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40354/abstract). Both disease incidence and disease severity were moderate prior to administration of the booster injection, with a maximum of 7 of 20 mice exhibiting arthritis symptoms. However, after secondary immunization, disease severity rapidly increased, and all mice eventually developed arthritis ( Figure 1A ).
We next correlated the incidence and severity of disease progression with lymphocyte activation in draining inguinal LNs and spleen following primary and secondary immunizations. We observed large increases in T cell and B cell populations in the inguinal LNs following the first (primary) immunization with CII, ranging from 2.3-fold (for FoxP+ Treg cells) to 8.9-fold for B-2 cells. These increases were greater than those in the spleen (maximum 2.9-fold), and cell expansion in the inguinal LNs largely dissipated following secondary immunization, with subsequent 1.8-fold to 6.2-fold decreases ( Figure 1B) . A notable exception to this pattern was that the spleen maintained durable expansion of the B-2 cell population (~3-fold) even after secondary immunization.
To determine whether GCs contribute to the B cell expansion following CIA, the B220+CD19+IgD-CD95+GL7+ cell population was quantified in the spleen and inguinal LNs following primary and secondary immunizations ( Figure 1C) . Notably, using this definition, the only major site of GC formation was the inguinal LNs following primary the immunization. As a second approach, we quantified the number of IgG1 B cells recognizing a triple-helix epitope at position 358-369 of CII (C1 epitope) and designated them as CD19+CD38+ (memory) or CD19+CD38-(GC). Using this criterion, we confirmed that inguinal LNs are a prominent site of anti-CII GC production following primary immunization; however, the spleen also contributed to CII-reactive GC populations following immunization ( Figure 1D ). In summary, CII immunization induced GC formation in inguinal LNs and to a lesser extent in spleen.
Novel mouse models of B cell-intrinsic loss of GC formation. Because CII immunization promoted multiple immune responses, we next sought to determine the contribution of GC formation to disease progression. To achieve this, we constructed 2 strains in which the B cell-specific transcription factor PAX-5 is conditionally deleted. Loss of PAX-5 within the B cell lineage leads to loss of B cell identity and function (29) (30) (31) . The first strain employed Cd23-Cre, which is expressed in transitional B cells (25) and efficiently deletes follicular and marginal zone B cells (32) , as well as memory B cells, following immunization (33) . The second strain is AicdaCre, which effectively deletes floxed alleles in the GC and has previously been utilized to abolish GC function (25, 34) . These 2 strains were additionally crossed onto a B6N.Q background to render them susceptible to CIA, and we thus generated Pax5 fl/-Cd23-Cre H-2 q and Pax5 fl/-Aicda-Cre H-2 q strains as well as relevant controls.
GCs IN CIA 195 We examined inguinal LNs and spleen on day 14 after primary immunization and on day 35 CD23-Cre strains completely lacked GC responses (Figure 2B ) and showed reduced numbers of plasma cells (PCs) in response to CIA. In contrast to these defined B cell defects, the Pax5 fl/-Aicda-Cre mice had normal numbers of T cells, whereas the Pax5 fl/-Cd23-Cre mice had small decreases in the number of CD4 central effector memory cells in the inguinal LNs relative to controls ( Figure 2C) . In both strains, the spleen showed no T cell defects (see Supplementary Figure 2B) . The selective loss of B cell function was also observed in the spleen and inguinal LNs on day 14 following primary immunization (see Supplementary Figure fl/-Cd23-Cre mice were completely protected against arthritis throughout this period ( Figure 3A) . We next sought to determine whether this protection was attributable to a failure in GC formation. We therefore repeated the experiment and included the Pax5 fl/-Aicda-Cre strain. Similar to the Pax5 fl/-Cd23-Cre mice, the Pax5 fl/-Aicda-Cre mice were also completely protected against CIA ( Figure 3B ). Finally, pooling of all control, Pax5 fl/-Aicda-Cre, and Pax5 fl/-Cd23-Cre mice from multiple experiments again showed highly significant (P < 0.0001) decreases in arthritis severity in experimental mice ( Figure 3C ). In summary, CIA was critically dependent on the formation of GCs.
Kinetics of humoral immune responses to CII. Because GC B cells are a source of increases in specific antibody responses, we next quantified the appearance of PCs in the spleen and inguinal LNs. Similar to the B cell responses, we observed an 11-fold increase in the number of PCs (defined as B220 low CD19 low CD138+CD28+) in the inguinal LNs after primary immunization and a decrease in these numbers 35 days after secondary immunization ( Figure 4A ). The spleen also showed a 2-fold increase in PC numbers that, in contrast to the inguinal LNs, was maintained after administration of the booster injection. To correlate humoral responses with this PC expansion, we performed enzyme-linked immunosorbent assay (ELISA) to measure and quantify total IgG antibody levels as well as specific humoral immune responses against CII. Large increases in both total IgG and IgG anti-CII antibody titers were observed after the primary injection, and these titers did not increase significantly after administration of a booster injection (Figures 4B and C).
We next assessed how loss of B-2 or GC lymphocytes in our mouse models would affect specific immunoglobulin responses. Total IgM levels were similar across all genotypes, and no specific IgM anti-CII responses could be detected, as previously reported (35) (Figure 5A) . In contrast, total IgG titers were strongly reduced (3.2-to 16-fold) in both Pax5 fl/-Aicda-Cre and Pax5 fl/-Cd23-Cre mouse strains when measured on day 5 and day 14 following primary immunization and day 35 after secondary immunization (day 70 after primary immunization). Additionally, anti-CII antibody responses were almost completely absent in both of the experimental strains ( Figure 5B ). On day 14 after primary immunization, we observed a 4.6-fold reduction in anti-CII responses in Pax5 fl/-Aicda-Cre mice relative to controls, with the residual anti-CII titers in the Pax5 fl/-Aicda-Cre strain probably corresponding to extrafollicular responses. In summary, anti-CII antibody responses were largely dependent on formation of the GC.
Reintroduction of arthritis through the exogenous supply of pathogenic antibodies. The requirement of GCs for arthritis induction indicated that GC-derived antibodies are critical for CIA. However, it remained possible that antigen presentation by cells within the GC may have a pathologic function distinct from B cell clonal selection (e.g., to facilitate T cell activation). We therefore subjected According to this protocol, 4 separate IgG antibodies recognizing CII are injected into the mice, and arthritis is induced (6) . Following performance of this procedure, both Pax5 fl/+ Aicda-Cre and Pax5 fl/-Aicda-Cre mice were fully susceptible to development of CAIA ( Figure 6A ), indicating that the requirement for GC formation in the pathology of CIA can be bypassed by the exogenous supply of disease-causing antibodies. There was, however, a trend toward a significant reduction in the frequency of CAIA (16% reduction) in Pax5 fl/-Aicda-Cre mice, indicating that GC B cells may have additional minor functions other than antibody secretion. Finally, by subsequently immunizing the mice with CII and quantifying antigenspecific T cells using specific tetramer staining, we confirmed that T cells reactive against CII could be produced in these GC-deficient mice. The CII peptide GalHyK264 is the galactosylated form of the CII 259-271 peptide, which is the major epitope recognized by T cells after CII immunization in MHC class A 
DISCUSSION
The B lymphocyte is a well-established mediator of arthritis, although the relative contribution of different B cell subtypes to disease pathogenesis is not currently known. In the present study, we obtained in vivo evidence that GC B cells are a major driver of CIA through the production of anti-CII antibodies.
It has been recognized that CII immunization induces the formation of GCs (36) , but a comprehensive analysis of the kinetics and localization of this response has been lacking. We now show that both the draining inguinal LNs and the spleen responded to CII by forming GCs. Notably, although the inguinal LNs appeared to respond more vigorously, equal amounts of CII-specific GCs were present in both inguinal LNs and spleen after secondary immunization, although memory cell responses appeared to be preferentially located in the inguinal LNs. There was also an increase in the titers of IgG and IgG1 against CII following secondary immunization, which correlated with increased disease severity and incidence. It was previously suggested that IgG2a anti-CII is the arthritogenic IgG isotype (37), but later 
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DAHDAH ET AL studies showed that IgG1 and IgG2b are also arthritogenic (38) . Studies using lMT -/-mice, which are genetically deficient in B cells, have indicated that B cells are important for the pathologic response to heterologous CII injection. We also showed that disease can be induced in lMT -/-mice through CAIA (39) . The interpretation of these results is complicated by additional defects in the organization of the spleen observed in this strain due to the important function of mature B cells in secreting lymphotoxin a (40). Additionally, because lMT -/-mice lack all mature B cells, it has not been possible to identify the subset or subsets that are pathogenic in CIA.
In addition to secreting antibodies, B cells can also function as antigen-presenting cells (41) . The relative contribution of B cells versus other professional antigen-presenting cells is a matter of debate. GC B cells clearly function as antigen-presenting cells to follicular helper T cells within the GC itself, and clonal competition for T cell help is a key affinity-based selection mechanism for affinity maturation (42) . Although we could efficiently induce arthritis in our Pax5 fl/-Aicda-Cre mouse strain by injecting previously cloned pathogenic antibodies, the extent of disease was marginally lower in this GC-deficient strain. This could be interpreted as GC B cells having other functions relevant to disease development. Clearly, however, a critical function of GC B cells in CIA is the production of anti-CII antibodies. This is further supported by studies showing that mice that lack GCs and additionally have broader immune defects also have reduced responses to CII (43, 44) , albeit on an MHC H-2 b background. Importantly, however, the B6 mouse model of CIA does not involve CII-reactive T cells, because the LPS was administered again on day 2. Disease scoring for CAIA was performed in a manner identical to that for collagen-induced arthritis (CIA). The number above the horizontal line is the fold change. The P value was determined by t-test. B, Left, Representative flow cytometry plots. Right, Absolute cell counts. CD4+CD3+ cells recognizing the major histocompatibility complex class II-loaded CII peptide GalHyK264 in the inguinal LNs (ILNs) and spleens of mice with CIA were quantified on day 35. In A and B (right), bars show the mean AE SEM. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40354/abstract. immune response is more likely to be triggered by heterologous proteins contaminating the CII preparations and will therefore be different from classic CIA in A q -expressing mice (28) . The contribution of GCs to clinical RA is not known. In RA, anti-citrullinated protein antibodies (ACPAs) and RFs (autoantibodies recognizing the Fc portion of immunoglobulins) are used routinely in the clinic for early classification of patients with RA. A mechanistic link between the GC and the pathogenesis of RA was postulated more than 55 years ago, with the observation that RFs can be located within structures resembling GCs (45) . These autoantibodies also appear to have a germline configuration (46) . ACPAs have been suggested to be somatically mutated (47, 48) and are clearly isotype-switched to IgG. This would imply that GCs in humans are also relevant for disease. However, whether ACPAs or RFs are pathogenic or in fact protect against the disease has not been clarified.
It is not known whether RA patients also develop systemic GCs in secondary lymphoid tissue. Interestingly, antibodies reacting to CII (AC2A) also arise in a subset of RA patients and are in particular produced in affected joints (49) . Although present in a minor subset of patients, it is important to note that the only antibodies that have so far been shown to induce arthritis are reactive with joint cartilage, including ACPAs that cross-react with CII (50) . The AC2A antibodies in RA are isotypeswitched, but there is currently no evidence that they are extensively somatically mutated, similar to the mouse model of CIA (3) . Alternatively, the GC reaction increases the absolute titers of antibodies and allows for class-switch recombination, both of which have critical effects in disease progression in addition to the affinity maturation process. Additional mechanisms, such as Th17 cells regulating the glycosylation pattern of anti-CII antibodies through interactions with plasmablasts emerging from the GC, could also be important (13) . Consistent with this, anti-CD20 therapy in RA patients can reduce autoantibody titers and the disease burden over an extended time period (51) , although the function of B cells in RA is likely to be complex and to involve functions in addition to antibody production.
In conclusion, we have demonstrated an indispensable role of GCs in CIA. Targeting the formation of B cell subtypes in clinical arthritis may help to further refine B cell-depleting therapies.
